BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis
- Conditions
- Healthy Subjects and Atopic Dermatitis Subjects
- Interventions
- Biological: BMS-981164Biological: Placebo matching with BMS-981164
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 93
- Registration Number
- NCT01614756
- Locations
- 🇬🇧
Local Institution, Nottingham, United Kingdom
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
- Conditions
- Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
- Interventions
- Biological: Ipilimumab
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT01611558
- Locations
- 🇺🇸
AdventHealth Cancer Institute, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Georgia Regents University, Augusta, Georgia, United States
Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects
- Conditions
- Healthy Adult Normals
- Interventions
- Drug: BMS-933043Drug: Placebo matching with BMS-933043Drug: Antacid Buffer Predose Solution
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT01605994
- Locations
- 🇺🇸
Clinilabs, Inc., New York, New York, United States
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
- Conditions
- HIV
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01605084
- Locations
- 🇺🇸
Anthony M. Mills Md Inc, Los Angeles, California, United States
🇺🇸Metropolis Medical Pc, San Francisco, California, United States
🇺🇸Be Well Medical Center, Berkley, Michigan, United States
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
- Conditions
- Hypertension
- Interventions
- Drug: BMS-823778Drug: Placebo matching with BMS-823778
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT01602367
- Locations
- 🇺🇸
Premier Research, Trenton, New Jersey, United States
🇺🇸Pharmquest, Llc, Greensboro, North Carolina, United States
🇺🇸Manassas Clinical Research Center, Manassas, Virginia, United States
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 881
- Registration Number
- NCT01598090
- Locations
- 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
- Conditions
- Chronic Phase Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 262
- Registration Number
- NCT01593254
- Locations
- 🇺🇸
Northern Indiana Cancer Research Consortium, Crown Point, Indiana, United States
🇺🇸Local Institution - 0006, Fontana, California, United States
🇮🇹Local Institution - 0021, Roma, Italy
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
- Conditions
- Non-Hodgkin's LymphomaMultiple MyelomaHodgkin Lymphoma
- Interventions
- Biological: NivolumabBiological: IpilimumabBiological: LirilumabBiological: DaratumumabDrug: PomalidomideDrug: Dexamethasone
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 316
- Registration Number
- NCT01592370
- Locations
- 🇺🇸
Local Institution - 0007, Philadelphia, Pennsylvania, United States
🇺🇸Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States
🇫🇷Local Institution - 0043, Poitiers, Vienne, France
Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins
- Conditions
- Atherosclerosis
- Interventions
- Biological: BMS-962476Biological: Placebo matching with BMS-962476
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 66
- Registration Number
- NCT01587365
- Locations
- 🇺🇸
Metabolic And Atherosclerosis Research Center/ Medpace Clinical Pharmacology, Cincinnati, Ohio, United States
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
- Conditions
- Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
- Interventions
- Other: Best Supportive care (BSC)Biological: Ipilimumab
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 143
- Registration Number
- NCT01585987
- Locations
- 🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸Nyu Clinical Cancer Center, New York, New York, United States
🇺🇸The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States